## Francisca Sivera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4030471/publications.pdf

Version: 2024-02-01

80 papers 1,758 citations

304368

22

h-index

288905 40 g-index

81 all docs

81 docs citations

times ranked

81

2009 citing authors

#	Article	IF	CITATIONS
1	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Annals of the Rheumatic Diseases, 2014, 73, 328-335.	0.5	222
2	Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Annals of the Rheumatic Diseases, 2007, 66, 1056-1058.	0.5	135
3	Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout. Arthritis Care and Research, 2015, 67, 1304-1315.	1.5	101
4	Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. Arthritis and Rheumatology, 2017, 69, 429-438.	2.9	93
5	Mechanisms of crystal formation in gout—a structural approach. Nature Reviews Rheumatology, 2015, 11, 725-730.	3.5	79
6	Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study. Arthritis and Rheumatology, 2016, 68, 1531-1539.	2.9	74
7	Gout, Hyperuricemia, and Crystalâ€Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care and Research, 2019, 71, 427-434.	1.5	<b>7</b> 3
8	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. RMD Open, 2019, 5, e001014.	1.8	73
9	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.5	72
10	Brief Report: Validation of a Definition of Flare in Patients With Established Gout. Arthritis and Rheumatology, 2018, 70, 462-467.	2.9	68
11	Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Seminars in Arthritis and Rheumatism, 2019, 49, 126-135.	1.6	66
12	Prevalencia de enfermedades reumáticas en población adulta en España (estudio EPISER 2016). Objetivos y metodologÃa. ReumatologÃa ClÃnica, 2019, 15, 90-96.	0.2	63
13	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. Annals of the Rheumatic Diseases, 2021, 80, 518-526.	0.5	54
14	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care and Research, 2016, 68, 667-672.	1.5	48
15	Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. Annals of the Rheumatic Diseases, 2017, 76, 1263-1268.	0.5	38
16	Performance of classification criteria for gout in early and established disease. Annals of the Rheumatic Diseases, 2016, 75, 178-182.	0.5	36
17	Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. Arthritis Care and Research, 2016, 68, 1894-1898.	1.5	34
18	Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries?. Rheumatology, 2020, 59, 2556-2562.	0.9	32

#	Article	IF	CITATIONS
19	Gout: optimizing treatment to achieve a disease cure. Therapeutic Advances in Chronic Disease, 2016, 7, 135-144.	1.1	27
20	Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated. Journal of Rheumatology, 2016, 43, 150-153.	1.0	25
21	Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice. Rheumatology and Therapy, 2018, 5, 243-253.	1.1	25
22	Methotrexate Is an Option for Patients With Refractory Calcium Pyrophosphate Crystal Arthritis. Journal of Clinical Rheumatology, 2012, 18, 234-236.	0.5	24
23	Therapy for CPPD: Options and Evidence. Current Rheumatology Reports, 2018, 20, 31.	2.1	24
24	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. Arthritis Care and Research, 2022, 74, 1649-1658.	1.5	23
25	Rheumatology training experience across Europe: analysis of core competences. Arthritis Research and Therapy, 2016, 18, 213.	1.6	19
26	Differences and similarities in rheumatology specialty training programmes across European countries. Annals of the Rheumatic Diseases, 2015, 74, 1183-1187.	0.5	18
27	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. RMD Open, 2018, 4, e000756.	1.8	17
28	EULAR â€~points to consider' for the conduction of workforce requirement studies in rheumatology. RMD Open, 2018, 4, e000780.	1.8	16
29	Rheumatology education in Europe: results of a survey of young rheumatologists. Clinical and Experimental Rheumatology, 2011, 29, 843-5.	0.4	16
30	Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology. RMD Open, 2016, 2, e000240.	1.8	14
31	Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. Seminars in Arthritis and Rheumatism, 2021, 51, 387-394.	1.6	13
32	Assessment of competences in rheumatology training: results of a systematic literature review to inform EULAR points to consider. RMD Open, 2020, 6, e001330.	1.8	12
33	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. Annals of the Rheumatic Diseases, 2021, 80, 65-70.	0.5	12
34	Diagnóstico y tratamiento de la gota. Medicina ClÃnica, 2017, 148, 271-276.	0.3	11
35	Flare Rate Thresholds for Patient Assessment of Disease Activity States in Gout. Journal of Rheumatology, 2021, 48, 293-298.	1.0	11
36	Managing Gout in the Patient with Renal Impairment. Drugs and Aging, 2018, 35, 263-273.	1.3	10

#	Article	IF	CITATIONS
37	Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study. RMD Open, 2020, 6, e001183.	1.8	9
38	Current advances in therapies for calcium pyrophosphate crystal arthritis. Current Opinion in Rheumatology, 2016, 28, 140-144.	2.0	8
39	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. Annals of the Rheumatic Diseases, 2019, 78, 1472-1479.	0.5	7
40	Prevalence of ankylosing spondylitis in Spain: EPISER2016 Study. Scandinavian Journal of Rheumatology, 2020, 49, 210-213.	0.6	7
41	Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?. Arthritis Research and Therapy, 2015, 17, 89.	1.6	6
42	Progresses in the imaging of calcium pyrophosphate crystal disease. Current Opinion in Rheumatology, 2020, 32, 140-145.	2.0	5
43	Estado, control, impacto y manejo actual de la artritis reumatoide según los pacientes: encuesta nacional AR 2020. ReumatologÃa ClÃnica, 2020, , .	0.2	5
44	Mixed Crystal Disease: A Tale of 2 Crystals. Journal of Rheumatology, 2020, 47, 1158-1159.	1.0	4
45	Prevalence of gout in the adult general population in Spain: Estimating the proportion of undiagnosed cases. Joint Bone Spine, 2022, 89, 105257.	0.8	4
46	Gout: Diagnosis and treatment. Medicina ClÃnica (English Edition), 2017, 148, 271-276.	0.1	3
47	Is Remission a Valid Target for Gout?. Journal of Rheumatology, 2020, 47, 4-5.	1.0	3
48	Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland. Annals of the Rheumatic Diseases, 2022, 81, e124-e124.	0.5	3
49	OP0339â€TOCILIZUMAB IN GIANT CELL ARTERITIS. MONOTHERAPY VERSUS COMBINED WITH CONVENTIONAL IMMUNOSUPPRESSIVE DRUGS. , 2019, , .		2
50	Current state, control, impact and management of rheumatoid arthritis according to patient: AR 2020 national survey. ReumatologÃa ClÃnica (English Edition), 2022, 18, 177-183.	0.2	2
51	EULAR portfolio for Rheumatology training: a EULAR School of Rheumatology initiative. RMD Open, 2021, 7, e001684.	1.8	2
52	Synovial Fluid Crystal Analysis. , 2012, , 20-34.		1
53	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: Ascertaining the Efficacy of Treatment Matters. American Journal of Medicine, 2015, 128, e41-e42.	0.6	1
54	Gout mimicking rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2016, 45, e28.	1.6	1

#	Article	IF	CITATIONS
55	Centre characteristics determine ambulatory care and referrals in patients with spondyloarthritis. Rheumatology International, 2016, 36, 1515-1523.	1.5	1
56	SAT0441â€SKIN ADVERSE EVENTS WITH FEBUXOSTAT IN GOUT PATIENTSWITH PREVIOUS SKIN REACTIONS TO ALLOPURINOL. A MULTICENTRE DESCRIPTIVE STUDY. , 2019, , .	ı	1
57	Prevalence of Rheumatic Diseases in Adult Population in Spain (EPISER 2016 Study): Aims and Methodology. ReumatologÃa ClÃnica (English Edition), 2019, 15, 90-96.	0.2	1
58	Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply. Rheumatology, 2021, 60, e120-e121.	0.9	1
59	Formación posgrado en ReumatologÃa: perspectiva en Europa. Seminarios De La Fundaciâ^šâ‰¥n Espaâ^šÂ±ola De Reumatologâ^šâ‰a, 2014, 15, 6-10.	0.1	O
60	Response to †Dual training in general internal medicine and rheumatology: the Irish context†by Dr Sheane. Annals of the Rheumatic Diseases, 2015, 74, e56-e56.	0.5	0
61	Gout and the heart: beyond comorbidities. International Journal of Clinical Rheumatology, 2015, 10, 329-334.	0.3	O
62	Centre-related variability in hospital admissions of patients with spondyloarthritis. Rheumatology International, 2016, 36, 1301-1308.	1.5	0
63	SAT0219â€EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS INDEPENDENTLY OF THE INICIAL PREDNISONE DOSE., 2019,,.		O
64	AB0577â€TOCILIZUMAB IN GIANT CELL ARTERITIS. ROUTE OF ADMINISTRACION: INTRAVENOUS OR SUBCUTANEOUS., 2019,,.		0
65	FRIO270â€APREMILAST IN NON-ULCER MANIFESTATIONS IN BEH§ET'S DISEASE. MULTICENTER STUDY OF CASES IN CLINICAL PRACTICE. , 2019, , .	32	O
66	THU0642â€EULAR POINTS TO CONSIDER FOR THE DEVELOPMENT, EVALUATION AND IMPLEMENTATION OF MOBILE HEALTH APPLICATIONS FOR SELF-MANAGEMENT IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES. , 2019, , .		0
67	THU0292â€EXTRACRANIAL VESSEL INVOLVEMENT IN PATIENTS WITH GIANT CELL ARTERITIS. , 2019, , .		О
68	FRIO276â€TIME OF DISEASE EVOLUTION AND EFFICACY OF TOCILIZUMAB IN GIANT CELL ARTERITIS. , 2019, , .		0
69	FRIO277â€ISCHEMIC AND SYSTEMIC SYMPTOMS IN GIANT CELL ARTERITIS PATIENTS, RESPONSE TO TOCILIZUMAB., 2019, , .		O
70	SAT0220â€USE OF TOCILIZUMAB IN AORTITIS. A MULTICENTER STUDY OF 79 PATIENTS. , 2019, , .		0
71	THU0313â€COMPARATIVE STUDY OF CLINICAL, ANALYTICAL AND VASCULAR 18F-FDG UPTAKE EVOLUTION IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH METHOTREXATE VS TOCILIZUMAB., 2019, , .		O
72	SAT0442â€CALCIUM PYROPHOSPHATE CRYSTAL ARTHRITIS DURING HOSPITALIZATIONS: A PROSPECTIVE, CRYSTAL-PROVEN CASE SERIES. , 2019, , .		0

#	Article	IF	CITATIONS
73	SAT0235â€BIOLOGICAL THERAPYIN NEUROBEHÇET. MULTICENTER STUDY OF 29 PATIENTS. , 2019, , .		O
74	SATO215â€APREMILAST IN REFRACTORY ORAL AND/OR GENITAL ULCERS IN BEHÇET'S DISEASE. MULTIC STUDY OF 49 CASES IN CLINICAL PRACTICE. , 2019, , .	ENTER	0
75	Crystal Analysis in Synovial Fluid. , 2019, , 47-58.		O
76	Gout. Journal of Clinical Rheumatology, 2020, 26, 208-212.	0.5	0
77	Myo-Spain: Registro de pacientes con miopatÃa inflamatoria idiopática de España. MetodologÃa. ReumatologÃa ClÃnica, 2021, , .	0.2	O
78	Myo-Spain: Spanish Registry of patients with idiopathic inflammatory myopathy. Methodology. ReumatologÃa ClÃnica (English Edition), 2021, , .	0.2	0
79	A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. ReumatologÃa ClÃnica, 2022, 18, 129-130.	0.2	O
80	A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. ReumatologÃa ClÃnica (English Edition), 2022, 18, 129-130.	0.2	O